MINITUBE INTERNATIONAL AG – Trademark Portfolio

Entity Type: 03

MINITUBE INTERNATIONAL AG holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 16 (Paper Goods) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include ANDROHEP and SPERMNOTES. The owner is based in TIEFENBACH.

HAUPTSTR. 41, 84184

TIEFENBACH , DE

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

MINITUBE INTERNATIONAL AG's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

16
Paper Goods (1 filing)

Paper and cardboard; printed matter; bookbinding material; photographs; stationery

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does MINITUBE INTERNATIONAL AG have?

MINITUBE INTERNATIONAL AG has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does MINITUBE INTERNATIONAL AG file in?

MINITUBE INTERNATIONAL AG files trademarks across 2 Nice Classification classes. The most active classes are Class 16 (Paper Goods), Class 5 (Pharmaceuticals). Class 16 covers paper and cardboard; printed matter; bookbinding material; photographs; stationery.

What are MINITUBE INTERNATIONAL AG's most well-known trademarks?

MINITUBE INTERNATIONAL AG's registered trademark portfolio includes well-known marks such as ANDROHEP and SPERMNOTES. These are among 2 currently registered trademarks in the portfolio.

What is MINITUBE INTERNATIONAL AG's trademark registration success rate?

MINITUBE INTERNATIONAL AG has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.